№ lp_1_2_27098
File format: docx
Character count: 34027
File size: 217 KB
This document provides detailed guidance for the administration of the MenACWY conjugate vaccine to individuals eligible for national vaccination programs or contacts of invasive meningococcal disease cases, in accordance with UK health policies.
Year:
2025
Region / city:
England
Topic:
Vaccination
Document Type:
Patient Group Direction (PGD)
Authorizing Body:
UK Health Security Agency (UKHSA)
Target Audience:
Healthcare professionals involved in immunization
Validity Period:
31 July 2025 – 31 December 2027
Review Date:
30 June 2027
Amendment History:
v1.0 to v6.0
Approval Date:
2 June 2025
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2025
Region / city:
England
Topic:
Immunization
Document type:
Patient Group Direction (PGD)
Organization / institution:
UK Health Security Agency (UKHSA)
Author:
Suki Hunjunt, Professor Shamez Ladhani, David Green
Target audience:
Healthcare professionals involved in immunization
Period of validity:
From 5 January 2026 to 5 January 2029
Approval date:
5 January 2026
Amendment date:
2 June 2025, 16 December 2025
Description:
A document detailing the administration guidelines for the pneumococcal polysaccharide conjugate vaccine (PCV13, PCV15) for children under 2 years old in the UK.
Reference no:
Hib/MenC PGD
Version no:
v6.0
Valid from:
1 July 2025
Expiry date:
30 April 2026
Authorising organisations:
UK Health Security Agency (UKHSA)
Target audience:
Registered healthcare practitioners
Responsible body:
UKHSA
Note:
Amendment history
v1.0 and v2.0:
See previous versions of this PGD template for details (19 January 2016 to 23 April 2018)
v3.0:
PHE Hib/MenC PGD amended to: include vaccination of individuals for the prevention of secondary cases of meningococcal group C disease (24 April 2018)
v4.0:
PHE Hib/MenC PGD amended to: remove reference to individuals with an underlying medical condition (5 March 2020)
v5.0:
UKHSA Hib/MenC PGD amended to: include minor rewording of standard text, layout and formatting changes (4 May 2022)
v6.0:
UKHSA Hib/MenC PGD amended to: include minor rewording, updated references, and changes to the childhood immunisation schedule (2 June 2025)
Developed by:
Christina Wilson (Lead Pharmacist), Professor Shamez Ladhani (Paediatric Infectious Diseases Consultant), David Green (Nurse Consultant for Immunisation Programmes)
Peer-reviewed by:
UKHSA Immunisations PGD Expert Panel
Date approved:
2 June 2025
Year:
2025
Region / city:
England
Topic:
Immunization
Document type:
Patient Group Direction (PGD)
Authoring body:
UK Health Security Agency (UKHSA)
Target audience:
Healthcare professionals involved in immunization programs
Period of validity:
17 December 2025 - 17 December 2028
Approval date:
9 December 2025
Review date:
17 July 2028
Expiry date:
17 December 2028
Year:
2021
Region / City:
Australia
Topic:
Pneumococcal vaccine submission
Document type:
Submission for listing on the National Immunisation Program
Author:
Merck Sharp & Dohme (Australia) Pty Ltd
Target audience:
Health professionals, regulatory bodies, policy makers
Period of validity:
Ongoing
Approval date:
16 July 2021 (FDA approval), 14 October 2021 (EMA recommendation)
Date of changes:
Not specified
Context:
A clinical submission for the inclusion of a 15-valent pneumococcal conjugate vaccine (PCV15) on the National Immunisation Program for adults at risk of pneumococcal disease.
Year:
2023
Region / city:
Australia
Subject:
Pneumococcal vaccine
Document type:
Submission
Organ / institution:
Therapeutic Goods Administration (TGA), Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Pfizer Australia Pty Ltd
Target audience:
Healthcare professionals, public health policymakers
Period of validity:
Ongoing
Approval date:
27 April 2023 (FDA approval)
Amendment date:
20 December 2022 (TGA submission)
Background:
This document presents the submission for the 20-valent pneumococcal conjugate vaccine to be listed on the National Immunisation Program in Australia for specific paediatric populations.
Year:
2017
Region / city:
Australia
Theme:
Meningococcal Vaccination
Document Type:
Application for Vaccine Listing
Organization / institution:
National Immunization Program (NIP)
Author:
Pfizer Australia Pty Ltd
Target Audience:
Health professionals, adolescents, school-based vaccination program administrators
Validity Period:
Not specified
Approval Date:
29 August 2013
Amendment Date:
Not specified
Note:
Contextual description
Year:
2023
Region / city:
Australia
Topic:
Pneumococcal vaccination
Document type:
Submission
Agency / organization:
Australian Technical Advisory Group on Immunisation (ATAGI)
Author:
Merck Sharp & Dohme (Australia) Pty Ltd
Target audience:
Healthcare professionals involved in immunization
Period of validity:
Not specified
Approval date:
Expected by 30 April 2023
Date of changes:
9 February 2023
Year:
2016
Region / City:
Australia
Theme:
Pneumococcal disease prevention
Document Type:
Submission
Organization / Institution:
Pfizer Australia Pty Ltd
Author:
Pfizer Australia Pty Ltd
Target Audience:
Healthcare professionals, policymakers, public health authorities
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2015
Region / city:
United Kingdom
Topic:
Immunisation
Document type:
Public Health Guideline
Organization / institution:
Public Health England
Author:
Elizabeth Graham, Mary Ramsay, David Green
Target audience:
Healthcare professionals, Registered Nurses, Paramedics
Period of validity:
From 15 December 2015 to 30 November 2017
Approval date:
15 December 2015
Amendment date:
N/A
Expiry date:
30 November 2017
Version:
v01.00
Review date:
1 June 2017
Reference number:
DTaP/IPV/Hib PGD
Note:
Change history
Version 1.00:
New PHE PGD template, 15 December 2015
Year:
2026
Field:
Biotechnology / Pharmacology
Document type:
Research article
Institution:
Mersana Therapeutics
Authors:
Aleksandr Yurkovetskiy, Natalya Bodyak, Mao Yin, Joshua D. Thomas, Susan M. Clardy, Patrick R. Conlon, Cheri A. Stevenson, Alex Uttard, LiuLiang Qin, Dmitry R. Gumerov, Elena Ter-Ovaneysan, Charlie Bu, Alex Johnson, Venu R. Gurijala, Dennis McGillicuddy, Michael J. DeVit, Laura L. Poling, Marina Protopopova, Ling Xu, Qingxiu Zhang, Peter U. Park, Donald A. Bergstrom, Timothy B. Lowinger
Keywords:
Antibody-drug conjugate, polymer, bystander effect, auristatin
Target organism:
Human HER2-positive and low-HER2-expression tumors
Experimental models:
Mice, rats, cynomolgus monkeys
Payload:
Auristatin F-hydroxypropylamide
Drug-antibody ratio (DAR):
10–15
Comparative analysis:
Trastuzumab-Dolaflexin vs ado-trastuzumab emtansine
Safety evaluation:
Pharmacokinetics, tumor regressions, toxicity profile
Description:
Original research article detailing the synthesis, characterization, and in vivo evaluation of Dolaflexin, an auristatin-based antibody-drug conjugate with a high drug-antibody ratio and controlled bystander effect, including comparative studies with existing ADC platforms.
Year:
2026
Type of document:
Research article / Supplemental methods
Subject:
Oncology, antibody–drug conjugates
Authors:
Wan-Fen Li, Ming-Feng Chiang, Hao-Cheng Weng, Jhih-Jie Yang, Hsin-Shan Wu, Szu-Yu Wu, Yu-Jung Chen, Chi‐Huan Lu, Jyy-Shiuan Tu, Ren-Yu Hsu, Chi-Sheng Shia, Teng-Yi Huang, Ming-Tain Lai
Affiliation:
Various research institutions (detailed in original publication)
Experimental models:
Multiple human and murine cancer cell lines, PDX models
Key molecules studied:
OBI-992, exatecan, Dato-DXd
Assays performed:
Hydrophobic interaction chromatography, RPLC-UV, LC/MS/MS, flow cytometry, ELISA, ATP measurement, RNA-seq
Cell lines:
NCI-N87, BxPC3, HCC827, NCI-H1975, MDA-MB-231, Capan-1, ES-2/GFP, MC38, HCC827/ABCB1, HCC827/ABCG2, Caco-2
Key outcomes measured:
DAR distribution, IC50 values, TROP2 expression, immunogenic cell death markers, ABC transporter expression
Data sources:
Crown Bioscience, WuXi Biologics, Human Protein Atlas
Reference no:
Hib/MenC PGD
Version no:
v6.0
Valid from:
1 July 2025
Expiry date:
30 April 2026
Authorising organisations:
UK Health Security Agency (UKHSA)
Target audience:
Registered healthcare practitioners
Responsible body:
UKHSA
Note:
Amendment history
v1.0 and v2.0:
See previous versions of this PGD template for details (19 January 2016 to 23 April 2018)
v3.0:
PHE Hib/MenC PGD amended to: include vaccination of individuals for the prevention of secondary cases of meningococcal group C disease (24 April 2018)
v4.0:
PHE Hib/MenC PGD amended to: remove reference to individuals with an underlying medical condition (5 March 2020)
v5.0:
UKHSA Hib/MenC PGD amended to: include minor rewording of standard text, layout and formatting changes (4 May 2022)
v6.0:
UKHSA Hib/MenC PGD amended to: include minor rewording, updated references, and changes to the childhood immunisation schedule (2 June 2025)
Developed by:
Christina Wilson (Lead Pharmacist), Professor Shamez Ladhani (Paediatric Infectious Diseases Consultant), David Green (Nurse Consultant for Immunisation Programmes)
Peer-reviewed by:
UKHSA Immunisations PGD Expert Panel
Date approved:
2 June 2025
Year:
2025
Region / City:
United Kingdom
Topic:
Meningococcal Disease, Ciprofloxacin, Public Health
Document Type:
Clinical Guidance
Organization / Institution:
UK Health Security Agency (UKHSA)
Author:
Shilan Ghafoor, Dr. Shamez Ladhani, Kate Wedgwood
Target Audience:
Healthcare Practitioners, Public Health Authorities
Period of Validity:
From 20 October 2025
Approval Date:
10 October 2025
Expiry Date:
19 October 2028
Review Date:
19 October 2027
Year:
2023
Region / City:
Massachusetts
Topic:
Meningococcal disease, Vaccination requirements
Document type:
Health advisory
Institution:
Massachusetts Department of Public Health
Author:
Massachusetts Department of Public Health
Target audience:
College and residential school students, Parents and legal guardians
Period of validity:
Ongoing
Approval date:
Not specified
Amendment date:
Not specified
Year:
2025
Region / City:
England
Topic:
Immunisation, Vaccination
Document Type:
Patient Group Direction (PGD)
Organization:
UK Health Security Agency (UKHSA)
Author:
Suki Hunjunt, Professor Shamez Ladhani, David Green
Target Audience:
Healthcare practitioners (registered)
Period of validity:
1 August 2025 - 1 August 2027
Approval Date:
9 June 2025
Review Date:
1 February 2027
Amendment Date:
7 July 2025
Year:
2025
Region / City:
England
Topic:
Meningococcal Disease, Vaccination
Document Type:
Patient Group Direction (PGD)
Organization / Institution:
UK Health Security Agency (UKHSA)
Author:
UK Health Security Agency
Target Audience:
Healthcare practitioners, NHS organizations
Period of validity:
1 July 2025 - 28 February 2028
Approval Date:
2 June 2025
Amendments Date:
11 December 2024, 7 December 2022, 28 January 2021, 21 December 2018, 24 April 2018, 3 February 2017, 21 July 2015
Note:
Context
Year:
2024
Region / city:
England
Theme:
Vaccination, Meningococcal Disease
Document type:
Patient Group Direction (PGD)
Institution:
UK Health Security Agency (UKHSA)
Author:
Suki Hunjunt, Mary Ramsay, David Green
Target audience:
Healthcare practitioners
Period of validity:
From 28 February 2025 to 28 February 2028
Approval date:
11 December 2024
Revision date:
7 December 2022
Expiry date:
28 February 2028
Content changes:
Minor rewording and updates for clarity and consistency, updated qualifications and professional registration
Purpose:
Facilitates the administration of the meningococcal group B vaccine in individuals with increased risk from Neisseria meningitidis group B in the UK
Year:
2017
Region / city:
Australia
Theme:
Meningococcal Vaccination
Document Type:
Application for Vaccine Listing
Organization / institution:
National Immunization Program (NIP)
Author:
Pfizer Australia Pty Ltd
Target Audience:
Health professionals, adolescents, school-based vaccination program administrators
Validity Period:
Not specified
Approval Date:
29 August 2013
Amendment Date:
Not specified
Note:
Contextual description